ArticleActa pharmaceutica Sinica. B2021
Organic carbon monoxide prodrug, BW-CO-111, in protection against chemically-induced gastric mucosal damage.
Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Oral Delivery Systems for Gasotransmitters in Therapeutic Applications.Polymer science & technology (Washington, D.C.) · 2026Review
- Review on recent advancements in understanding acetylsalicylic acid-induced gastrointestinal injury: mechanisms, medication, and dosage refinement.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Carbon monoxide potentiates the effect of corticosteroids in suppressing inflammatory responses in cell culture.Bioorganic & medicinal chemistry · 2025Article
- Carbon Monoxide as a Potential Therapeutic Agent: A Molecular Analysis of Its Safety Profiles.Journal of medicinal chemistry · 2024Review
- On the Question of CO's Ability to Induce HO-1 Expression in Cell Culture: A Comparative Study Using Different CO Sources.ACS chemical biology · 2024Article
- Hydrogen Sulfide-Releasing Indomethacin-Derivative (ATB-344) Prevents the Development of Oxidative Gastric Mucosal Injuries.Antioxidants (Basel, Switzerland) · 2023Article
- Click chemistry and drug delivery: A bird's-eye view.Acta pharmaceutica Sinica. B · 2023Review
- Toward "CO in a Pill": Silica-Immobilized Organic CO Prodrugs for Studying the Feasibility of Systemic Delivery of CO viaMolecular pharmaceutics · 2023Article
- De Novo Construction of Fluorophores via CO Insertion-Initiated Lactamization: A Chemical Strategy toward Highly Sensitive and Highly Selective Turn-On Fluorescent Probes for Carbon Monoxide.Journal of the American Chemical Society · 2023Article
- Identification and verification of ferroptosis-related genes in gastric intestinal metaplasia.Frontiers in genetics · 2023Article
- Carbon Monoxide Signaling: Examining Its Engagement with Various Molecular Targets in the Context of Binding Affinity, Concentration, and Biologic Response.Pharmacological reviews · 2022Review
- Delivery of therapeutic carbon monoxide by gas-entrapping materials.Science translational medicine · 2022Article
- Carbon monoxide signaling and soluble guanylyl cyclase: Facts, myths, and intriguing possibilities.Biochemical pharmacology · 2022Review
- Glucagon-like peptide-2 protects the gastric mucosaFrontiers in endocrinology · 2022Article
- Redox and catalase-like activities of four widely used carbon monoxide releasing molecules (CO-RMs).Chemical science · 2021Article
- "CO in a pill": Towards oral delivery of carbon monoxide for therapeutic applications.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Adapting decarbonylation chemistry for the development of prodrugs capable ofChemical science · 2021Article
- Carbon Monoxide and Nitric Oxide as Examples of the Youngest Class of Transmitters.International journal of molecular sciences · 2021Review
- Nature's marvels endowed in gaseous molecules I: Carbon monoxide and its physiological and therapeutic roles.Acta pharmaceutica Sinica. B · 2021Review
- Novel Hydrogen Sulfide (HInternational journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-based carbon monoxide (CO)-releasing molecules have been shown to exert anti-inflammatory and anti-oxidative properties maintaining gastric mucosal integrity. We are interested in further development of metal-free CO-based therapeutics for oral administration. Thus, we examine the protective effect of representative CO prodrug, BW-CO-111, in rat models of gastric damage induced by necrotic ethanol or aspirin, a representative non-steroidal anti-inflammatory drug. Treatment effectiveness was assessed by measuring the microscopic/macroscopic gastric damage area and gastric blood flow by laser flowmetry. Gastric mucosal mRNA and/or protein expressions of HMOX1, HMOX2, nuclear factor erythroid 2-related factor 2, COX1, COX2,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.